Database startup Supabase announced a $500 million funding round that values the company at $10.5 billion, including the fresh capital. Supabase provides back-end technology for vibe coders. "I built ...

Meta is testing a new subscription service for Instagram that offers users "exclusive" features like the ability to post Stories for longer than 24 hours. Screenshots promoting "Instagram Plus" have ...

Kari McCaw was flying with co-workers to attend a conference in Las Vegas last month when Southwest Airlines employees stopped her at the ticket counter. The agents’ message was clear — either buy a ...

SQL Server backups cannot be restored to older versions directly. Use Export and Import Data-Tier Application for cross-version database migration. Reconfigure permissions, logins, and connection ...

DBeaver is a free, open-source, cross-platform SQL client and database administration tool. It is designed to support a wide variety of SQL and NoSQL databases, including MySQL and PostgreSQL. Its key ...

The Television Academy has announced that the Scripted Variety and Talk Series categories will once again merge to form one Outstanding Variety Series category for the 2026 Emmys. New rules allow for ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. However, there's one big ...

"I can't keep doing this," Sarah told me in our first session. Successful professional, mother of two, by all external measures thriving. "I value my career. I worked hard to build it. But I also ...

Blenrep, combined with Velcade and dexamethasone, is approved for relapsed/refractory multiple myeloma after two prior therapies, showing significant survival benefits. The phase 3 DREAMM-7 trial ...

A dual-SIM setup lets you use one phone to make and receive calls and texts from two numbers. It's also super convenient and can save you serious cash when traveling. We show you how to use two SIMs ...

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study Patients with ≥1 prior line of therapy were ...